Skip to main content

Table 1 Comparison of demographic characteristics and perioperative factors between HA and non-HA groups in patients undergoing THA after stratified by preoperative serum albumin levels*

From: Incidence and risk factors associated with human albumin administration following total joint arthroplasty: a multicenter retrospective study

Variable

Pre-ALB < 35 g/L

Pre-ALB ≥ 35 g/L

Overall (n = 441)

HA (n = 297)

No HA (n = 144)

P value†

Overall (n = 4272)

HA (n = 661)

No HA (n = 3611)

P value†

Age (years)

   

0.593

   

0.001

 ≤ 64

253 (57.4)

175 (69.2)

78 (30.8)

 

2932 (68.6)

414 (14.1)

2518 (85.9)

 

 65–79

137 (31.1)

90 (65.7)

47 (34.3)

 

1194 (27.9)

219 (18.3)

975 (81.7)

 

 ≥ 80

51 (11.6)

32 (62.7)

19 (37.3)

 

146 (3.4)

28 (19.2)

118 (80.8)

 

Sex

   

0.069

   

0.019

 Male

205 (46.5)

147 (71.7)

58 (28.3)

 

2015 (47.2)

284 (14.1)

1731 (85.9)

 

 Female

236 (53.5)

150 (63.6)

86 (36.4)

 

2257 (52.8)

377 (16.7)

1880 (83.3)

 

BMI (kg/m2)

   

0.084

   

0.120

 < 18.5

45 (10.2)

31 (68.9)

14 (31.1)

 

229 (5.4)

46 (20.1)

183 (79.9)

 

 18.5–24.9

281 (63.7)

178 (63.3)

103 (36.7)

 

2639 (61.8)

412 (15.6)

2227 (84.4)

 

 25.0–29.9

103 (23.4)

78 (75.7)

25 (24.3)

 

1184 (27.7)

176 (14.9)

1008 (85.1)

 

 ≥ 30

12 (2.7)

10 (83.3)

2 (16.7)

 

220 (5.1)

27 (12.3)

193 (87.7)

 

Diagnosis

   

0.008

   

0.001

 ONFH

157 (35.6)

108 (68.8)

49 (31.2)

 

1420 (33.2)

179 (12.6)

1241 (87.4)

 

 DDH

25 (5.7)

16 (64.0)

9 (36.0)

 

842 (19.7)

125 (14.8)

717 (85.2)

 

 OA

55 (12.5)

48 (87.3)

7 (12.7)

 

872 (20.4)

161 (18.5)

711 (81.5)

 

 HF

110 (24.9)

66 (60.0)

44 (40.0)

 

394 (9.2)

69 (17.5)

325 (82.5)

 

 Others

94 (21.3)

59 (62.8)

35 (37.2)

 

744 (17.4)

127 (17.1)

617 (82.9)

 

ASA class

   

0.075

   

< 0.001

 1

169 (38.3)

103 (60.9)

66 (39.1)

 

1471 (34.4)

168 (11.4)

1303 (88.6)

 

 2

226 (51.2)

162 (71.7)

64 (28.3)

 

2461 (57.6)

430 (17.5)

2031 (82.5)

 

 ≥ 3

46 (10.4)

32 (69.6)

14 (30.4)

 

340 (8.0)

63 (18.5)

277 (81.5)

 

Anemia

   

0.002

   

< 0.001

 Yes

212 (48.1)

158 (74.5)

54 (25.5)

 

1725 (40.4)

318 (18.4)

1407 (81.6)

 

 No

229 (51.9)

139 (60.7)

90 (39.3)

 

2547 (59.6)

343 (13.5)

2204 (86.5)

 

Surgical type

   

0.835

   

0.024

 Primary unilateral

388 (88.0)

263 (67.8)

125 (32.2)

 

3873 (90.7)

602 (15.5)

3271 (84.5)

 

 Primary bilateral

32 (7.3)

21 (65.6)

11 (34.4)

 

221 (5.2)

23 (10.4)

198 (89.6)

 

 Revision unilateral

21 (4.8)

13 (61.9)

8 (38.1)

 

178 (4.2)

36 (20.2)

142 (79.8)

 

Anesthesia

   

0.028

   

0.001

 General

373 (84.6)

259 (69.4)

114 (30.6)

 

3635 (85.1)

591 (16.3)

3044 (83.7)

 

 Spinal + epidural + CSE

68 (15.4)

38 (55.9)

30 (44.1)

 

637 (14.9)

70 (11.0)

567 (89.0)

 

Anticoagulant use

   

0.040

   

0.043

 Yes

418 (94.8)

286 (68.4)

132 (31.6)

 

4094 (95.8)

643 (15.7)

3451 (84.3)

 

 No

23 (5.2)

11 (47.8)

12 (52.2)

 

178 (4.2)

18 (10.1)

160 (89.9)

 

TXA use

   

0.758

   

0.492

 Yes

167 (37.9)

111 (66.5)

56 (33.5)

 

2771 (64.9)

421 (15.2)

2350 (84.8)

 

 No

274 (62.1)

186 (67.9)

88 (32.1)

 

1501 (35.1)

240 (16.0)

1261 (84.0)

 

Colloid solution use

   

0.173

   

< 0.001

 Yes

292 (66.2)

203 (69.5)

89 (30.5)

 

2349 (55.0)

418 (17.8)

1931 (82.2)

 

 No

149 (33.8)

94 (63.1)

55 (36.9)

 

1923 (45.0)

243 (12.6)

1680 (87.4)

 

Drain use

   

0.002

   

< 0.001

 Yes

405 (91.8)

281 (69.4)

124 (30.6)

 

3516 (82.3)

624 (17.7)

2892 (82.3)

 

 No

36 (8.2)

16 (44.4)

20 (55.6)

 

756 (17.7)

37 (4.9)

719 (95.1)

 

Transfusion use

   

0.970

   

0.251

 Yes

77 (17.5)

52 (67.5)

25 (32.5)

 

792 (18.5)

112 (14.1)

680 (85.9)

 

 No

364 (82.5)

245 (67.3)

119 (32.7)

 

3480 (81.5)

549 (15.8)

2931 (84.2)

 
  1. *Data are reported as number (%); †p-value calculated using Pearson chi-square test or Fisher exact test
  2. ASA American Society of Anesthesiologists, BMI body mass index, CSE combined spinal-epidural, DDH development dysplasia of hip, HA human albumin, HF hip fracture, OA osteoarthritis, ONFH osteonecrosis of femoral head, Pre-ALB preoperative albumin, THA total hip arthroplasty, TXA tranexamic acid